Janney Montgomery Scott LLC cut its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 50.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 160,926 shares of the company’s stock after selling 163,622 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Astrazeneca were worth $31,738,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE grew its position in shares of Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares during the period. Fisher Asset Management LLC increased its stake in shares of Astrazeneca by 2.1% during the 4th quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock worth $3,791,051,000 after purchasing an additional 438,709 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Astrazeneca by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock valued at $3,537,684,000 after purchasing an additional 445,014 shares during the period. Morgan Stanley raised its holdings in shares of Astrazeneca by 3.2% in the 4th quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock valued at $2,435,716,000 after purchasing an additional 432,939 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Astrazeneca by 9.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock valued at $521,517,000 after purchasing an additional 582,183 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
AZN has been the subject of a number of research analyst reports. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $205.33.
Astrazeneca Stock Performance
Shares of AZN stock opened at $190.93 on Tuesday. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The company has a market capitalization of $296.11 billion, a price-to-earnings ratio of 28.67, a PEG ratio of 1.64 and a beta of 0.25. The company has a 50-day simple moving average of $184.38 and a 200 day simple moving average of $187.32. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.
Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, sell-side analysts predict that Astrazeneca Plc will post 9.39 earnings per share for the current year.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Further Reading
- Five stocks we like better than Astrazeneca
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
